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Fertility Preservation in Children, Adolescents, and Young
Adults With Cancer: Quality of Clinical Practice Guidelines
and Variations in Recommendations
Anna Font-Gonzalez, MSc1; Renee L. Mulder, MSc, PhD1; Erik A.H. Loeffen, MD2; Julianne Byrne, PhD3;
Eline van Dulmen-den Broeder, PhD4; Marry M. van den Heuvel-Eibrink, MD, PhD5; Melissa M. Hudson, MD6;
Lisa B. Kenney, MD, MPH7; Jennifer M. Levine, MD, MSW8; Wim J.E. Tissing, MD, PhD2;
Marianne D. van de Wetering, MD, PhD1; and Leontien C. M. Kremer, MD, PhD1;
on behalf of the PanCareLIFE Consortium
BACKGROUND: Fertility preservation care for children, adolescents, and young adults (CAYAs) with cancer is not uniform among prac-
titioners. To ensure high-quality care, evidence-based clinical practice guidelines (CPGs) are essential. The authors identified existing
CPGs for fertility preservation in CAYAs with cancer, evaluated their quality, and explored differences in recommendations. METHODS:
A systematic search in PubMed (January 2000-October 2014); guideline databases; and Web sites of oncology, pediatric, and fertility
organizations was performed. Two reviewers evaluated the quality of the identified CPGs using the Appraisal of Guidelines for
Research and Evaluation II Instrument (AGREE II). From high-quality CPGs, the authors evaluated concordant and discordant areas
among the recommendations. RESULTS: A total of 25 CPGs regarding fertility preservation were identified. The average AGREE II do-
main scores (scale of 0%-100%) varied from 15% on applicability to 100% on clarity of presentation. The authors considered 8 CPGs
(32%) to be of high quality, which was defined as scores 60% in any 4 domains. Large variations in the recommendations of the high-
quality CPGs were observed, with 87.2% and 88.6%, respectively, of discordant guideline areas among the fertility preservation recom-
mendations for female and male patients with cancer. CONCLUSIONS: Only approximately one-third of the identified CPGs were found
to be of sufficient quality. Of these CPGs, the fertility preservation recommendations varied substantially, which can be a reflection of
inadequate evidence for specific recommendations, thereby hindering the ability of providers to deliver high-quality care. CPGs includ-
ing a transparent decision process for fertility preservation can help health care providers to deliver optimal and uniform care, thus
improving the quality of life of CAYAs with cancer and cancer survivors. Cancer 2016;122:2216-23. VC 2016 The Authors. Cancer published
by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly
cited, the use is non-commercial and no modifications or adaptations are made.
KEYWORDS: childhood cancer, evidence-based medicine, fertility preservation, guidelines, pediatric oncology.
INTRODUCTION
Over the last several decades, the survival of patients with childhood cancer has increased significantly due to advances in
treatment. In Europe and the United States alone, nearly 80% of children, adolescents, and young adults (CAYAs) survive
5 years from a cancer diagnosis, with the vast majority expected to achieve extended long-term survival into adulthood.1,2
As the number of childhood cancer survivors increases, the long-term side effects of treatment gain greater importance. Of
particular concern is the substantially elevated risk of fertility impairment after treatment of childhood cancer, especially
after treatment with alkylating agents (and similar DNA interstrand cross-linking agents) and/or radiation to fields that
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expose the ovaries or testes.3-6 Fertility impairment has se-
rious consequences for quality of life among newly diag-
nosed patients, their parents, and adults surviving
childhood cancer.7,8
Interventions currently can be offered to individuals
diagnosed with cancer to preserve their fertility poten-
tial.9,10 Survey data have indicated that many patients,
especially females, are not or are inadequately counseled
regarding the potential adverse effects of treatment on fer-
tility and even fewer are referred for fertility preservation.
Uniformity of counseling and standards for referral are
lacking when fertility preservation is offered, which leads to
variability in the uptake of these procedures.11,12 To ensure
that CAYAs who are diagnosed with cancer receive high-
quality uniform care, evidence-based clinical practice
guidelines (CPGs) are essential. CPGs are defined by the
Institute of Medicine as “statements that include recom-
mendations intended to optimize patient care that are
informed by a systematic review of evidence and an assess-
ment of the benefits and harms of alternative care
options.”13 CPGs are important to improve the quality of
care and to reduce variability in daily practice and
costs.14,15 In addition, the design of CPGs bridges the gap
between research and clinical practice. However, CPGs in
oncology are not always the result of methodologically
sound and evidence-based research.16 A comprehensive
assessment of the existing CPGs in fertility preservation for
CAYAs with cancer including the variations in recommen-
dations is needed as a first step toward developing an inter-
national, uniform, and harmonized CPG.17 This effort is
part of the PanCareLIFE, a European Union-funded pro-
ject that aims to advance the state-of-the-art in CPGs for
fertility preservation counseling by developing CPGs for
males and females requiring potentially gonadotoxic cancer
treatment modalities and to support health care providers
as well as survivors and their families in making informed
treatment and intervention choices based on personalized
risk assessments.18 The objective of the current study was
to identify existing CPGs for fertility preservation in
CAYAs diagnosed with cancer, evaluate their quality, and
explore differences in recommendations.
MATERIALS AND METHODS
Identification of Existing CPGs
We explored established national and international guide-
line databases and organizations known to produce
evidence-based CPGs. We also searched CPGs published
by oncology and pediatric professional organizations as
well as fertility organizations (see online Supporting In-
formation Table S1). In addition, we consulted experts in
the field of pediatric oncology and gynecology, and
experts in our PanCareLIFE Consortium to identify exist-
ing CPGs. We also systematically searched in PubMed for
CPGs published between January 1, 2000 and October 1,
2014. The search strategy was developed in collaboration
with the Cochrane Childhood Cancer Group, and com-
prised the following terms: “fertility preservation,”
“cancer,” “children/young adult,” and “guidelines” (see
online Supporting Information SMethods 1 for full search
strategy). Articles were independently selected on the basis
of title and abstract by 2 reviewers (A.F.G. and R.L.M.)
using the following inclusion criteria: evidence-based
CPGs (presenting evidence and recommendations) cover-
ing fertility preservation and written in English or Dutch.
To avoid being restrictive, we included CPGs for chil-
dren, adolescents, and adults with cancer. We excluded
committee/expert opinion documents and review articles
with no recommendations. If the abstract was unavailable
electronically or if it provided insufficient information,
we retrieved the full-text article for more detailed exami-
nation. Discrepancies between review authors were
resolved by consensus. Finally, all selected records were
assessed in full text by the 2 reviewers (A.F.G. and
R.L.M.) to ensure eligibility.
Appraisal of Existing CPGs With Appraisal of
Guidelines for Research and Evaluation II
Instrument
We appraised the methodology of the identified CPGs using
the Appraisal of Guidelines for Research and Evaluation II
instrument (AGREE II).19 AGREE II comprises 23 key
items organized into 6 domains. Each domain covers a
unique dimension of practice guideline quality: scope and
purpose (domain 1); stakeholder involvement (domain 2);
rigor of development (domain 3); clarity of presentation (do-
main 4); applicability (domain 5); and editorial independ-
ence (domain 6). All documents related to the guideline (ie,
handbook or other supplementary information) were taken
into account when appraising the guideline quality.
Each guideline was independently assessed by 2
reviewers by assigning scores on a 7-point scale for each
key item. The workload was divided between 3 reviewers
(A.F.G. appraised 23 CPGs, R.L.M. appraised 13 CPGs,
and E.A.H.L. appraised 14 CPGs). Scoring discrepancies
of 3 points were discussed between the appraisers with-
out the desire to reach consensus but to ensure that no in-
formation was missing (see online Supporting
Information Table S3 for mean key item scores). Follow-
ing the formula established by AGREE II, standardized
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domain scores for each CPG were expressed on a scale of
0% to 100% and calculated by summing scores of indi-
vidual items and standardizing the total as a percentage of
the maximum possible score for that domain.19 We con-
sidered high-quality CPGs to be those that had scores
60% in any 4 (or more) AGREE II domains. As recom-
mended by AGREE II, we did not measure the overall
score that represents a combination of all 6 domains as
identifying criteria for high-quality CPG.19
Comparison of Existing CPGs
To compare the content and evaluate the discordant and
concordant areas in the identified high-quality CPGs, we
considered the following key questions: “Who should be
advised to receive fertility preservation?”, “What fertility
preservation method should be used?”, “When should fer-
tility preservation be discussed and initiated?”, “Who
should be involved in the counseling and decision making
about fertility preservation?”, and “What are the ethical
and logistical aspects?”. We subdivided each key issue in
specific items or guideline areas outlined in the content of
all of the CPGs. Thus, the number of guideline areas var-
ied per key issue. The first and second authors (A.F.G.
and R.L.M.) extracted for each guideline area the recom-
mendations from the high-quality CPGs. Any disagree-
ments were discussed and resolved by consensus.
A guideline area was considered as concordant
when all CPGs advised the same recommendation for
the specific guideline area. If this was not the case, the
guideline area was considered discordant. If a CPG did
not include a recommendation for a specific guideline
area or if only 1 guideline covered a specific guideline
area but the rest did not, we also considered that guide-
line area to be discordant, and we added a comment re-
ferring to this situation. If one guideline did not
present information at all regarding one key issue, we




In total, we identified 25 unique CPGs (Fig. 1). The
search regarding known guideline databases, cancer Web
sites, and pediatric and fertility organizations yielded 14
CPGs (see online Supporting Information Table S1). Af-
ter consulting experts in the field, we identified an addi-
tional 5 CPGs. From our systematic search in PubMed,
we identified 11 additional CPGs (Fig. 2). We excluded 5
CPGs that were updated versions of CPGs that already
had been identified.
Figure 1. Flowchart shows the results of searches for fertility
preservation clinical practice guidelines after a search in
guideline databases and organizations; searches in pediatric,
oncology, and fertility professional organizations; a consulta-
tion with experts in the field of pediatric oncology and gyne-
cology and experts in our PanCareLIFE Consortium; and a
systematic literature search in PubMed.
Figure 2. Flowchart shows the number of selected clinical
practice guidelines after the PubMed search.
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AGREE II Appraisal
We appraised the quality of the 25 identified CPGs using
AGREE II (Table 1).20-44 All CPGs identified were writ-
ten in English with the exception of 2 CPGs that were
written in Dutch.20,35
CPGs varied with regard to the extent of informa-
tion provided concerning fertility preservation. Some
CPGs provided comprehensive information regarding
fertility preservation for patients with cancer (such as the
American Society of Clinical Oncology (ASCO)23)
whereas others did not (eg, the Scottish Intercollegiate
Guidelines Network [SIGN]21). The majority of CPGs
addressed all cancer types, with the exception of 8 CPGs
that focused on specific cancer types including breast can-
cer (1 CPG), germ cell tumors (3 CPGs), Hodgkin lym-
phoma (2 CPGs), hematological tumors (1 CPG), and
endometrial tumors (1 CPG). The majority of CPGs (14
CPGs) considered fertility preservation for both sexes,
whereas others focused exclusively on either female (8
CPGs) or male (3 CPGs) patients with cancer (see online
Supporting Information Table S2). Eight of the 25
CPGs met the criteria to be considered a high-quality
CPG (ASCO,23 Fernbach et al,22 National Institute for
Health and Clinical Excellence [NICE],24 National Com-
prehensive Cancer Network (NCCN),26 SIGN [2011],21
SIGN [2013],25 Clinical Oncology Society of Australia
(COSA),27 and Nederlandse Vereniging voor Obstetrie en
Gynaecologie [Dutch Association for Obstetrics and Gyne-
cology] (NVOG)20) (Table 1).22-40 The mean item scores
in each CPG are shown in Supporting Information Table
S3. Overall, the highest mean domain score was for clarity
of presentation (95%) and the lowest was noted for
applicability (43%) (see online Supporting Information
SMethods 2).
TABLE 1. Results of AGREE II in 25 Identified Existing CPGs for Fertility Preservation in Children With Can-




















NVOG 200720 75% 78% 61% 81% 15% 63%
SIGN 201121 92% 89% 79% 97% 69% 54%
Fernbach 201422 89% 53% 66% 97% 15% 63%
ASCO 201323 86% 92% 77% 100% 48% 58%
NICE 201324 94% 83% 98% 94% 83% 71%
SIGN 201325 97% 83% 69% 100% 67% 79%
NCCN 201426 69% 61% 68% 94% 15% 67%
COSA 201127 92% 81% 66% 100% 29% 38%
Overall (mean) 87% 78% 73% 95% 43% 62%
Lower quality
BFS 200328 53% 44% 13% 72% 21% 0%
EGCCCG 200429 53% 22% 23% 47% 10% 0%
Wallace 200530 39% 8% 16% 39% 4% 29%
RCP 200731 50% 56% 18% 86% 21% 0%
Backhus 200732 42% 22% 4% 31% 4% 8%
AAP 200833 25% 8% 10% 44% 17% 25%
Tangjitgamol 200934 64% 11% 26% 50% 10% 0%
IKNL 200935 61% 53% 33% 58% 6% 38%
Cardoso 201236 58% 31% 35% 75% 8% 25%
Michaeli 201237 47% 17% 8% 50% 0% 0%
ISFP 201238 42% 19% 11% 56% 4% 0%
EAU 201539 42% 47% 55% 89% 29% 92%
ASRM 201340 58% 28% 42% 86% 15% 54%
AHS 201341 86% 28% 53% 89% 23% 71%
BCSH 201442 61% 36% 49% 97% 8% 29%
ISFP 201243 36% 8% 15% 42% 8% 25%
NZ 201444 58% 67% 53% 67% 25% 0%
Abbreviations: AAP, American Academy of Pediatrics; AGREE II, Appraisal of Guidelines for Research and Evaluation II Instrument; AHS, Alberta Health Serv-
ices; ASCO, American Society of Clinical Oncology; ASRM, American Society for Reproductive Medicine; BCSH, British Committee for Standards in Haematol-
ogy; BFS, British Fertility Society; COSA, Clinical Oncology Society of Australia; CPG, clinical practice guideline; EAU, European Association of Urology;
EGCCCG, European Germ Cell Cancer Consensus Group; ISFP, International Society for Fertility Preservation; IKNL, Integraal Kankercentrum Nederland [Neth-
erlands Comprehensive Cancer Organisation]; NCCN, National Comprehensive Cancer Network; NICE, National Institute for Health and Clinical Excellence;
NVOG, Nederlandse Vereniging voor Obstetrie en Gynaecologie [Dutch Association for Obstetrics and Gynecology]; NZ, National Child Cancer Network New
Zealand; RCP, Royal College of Physicians; SIGN, Scottish Intercollegiate Guidelines Network.
a Guidelines that met the criteria to be considered high quality (ie, with 60% in any 4 domains).
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Concordant and Discordant Fertility
Preservation Guideline Areas
Tables 2 and 3 as well as online Supporting Information
Tables S4 and S5 show the concordant and discordant
guideline areas among the high-quality CPGs. In both
males and females, recommendations for several specific
guideline areas were not mentioned. Overall, for female fer-
tility preservation, there was concordance among 6 of 47
guideline areas (12.8%) and discordance among 41 of 47
guideline areas (87.2%). Of the 6 concordant guideline
areas, the highest concordance rate was for the key issue
“Who should be advised to receive fertility preservation?”
(50%), followed by the key issue “What fertility preserva-
tion method should be used?” (16.7%), ‘When should fer-
tility preservation be discussed and initiated?’ and “Who
should be involved in the discussion of and decision for fer-
tility preservation?” (16.7%). The highest discordance rate
was found for the key issue ‘Who should be involved in the
counseling and decision making about fertility preserva-
tion?”(29.3%). We observed no concordant areas for the
key issue “What are the ethical and logistical aspects?”.
With regard to male fertility preservation CPGs, we
observed overall concordances in 5 of 44 guideline areas
(11.4%) and discordance in 39 of 44 guideline areas
(88.6%). The highest concordance rate was found for the
key issue “Who should be advised to receive fertility pres-
ervation?” (40%), followed by the key issues “What fertil-
ity preservation method should be used?” (20%), “When
should fertility preservation be discussed and initiated?”
(20%), and “What are the ethical and logistical
aspects?”(20%). The key issue “Who should be involved
in the counseling and decision making about fertility pres-
ervation?” presented no concordant areas.
DISCUSSION
In the current study, we observed considerable variability
among the recommendations of the selected high-quality
CPGs addressing fertility preservation. The lack of quality
and uniformity in the recommendations is likely to lead
to conflicting recommendations and reflects that the qual-
ity of clinical practice may not be optimal for all patients
with cancer.45 This supports the need for well-developed
and transparently harmonized CPGs for CAYAs diag-
nosed with cancer who are at risk of fertility impairment.
The guideline recommendations exhibited discord-
ance in 87.2% and 88.6%, respectively, of issues
addressed for female and male patients with cancer. This
discordance relates to conflicting recommendations
between guidelines and also to some of the guidelines
TABLE 2. Concordant and Discordant Guideline Areas in High-Quality Female Fertility Preservation CPGs
Concordanta % per Row Discordantb % per Row Total
Who should be advised to receive fertility preservation? 3 27.3 8 72.7 11
What fertility preservation method should be used? 1 14.3 6 85.7 7
When should fertility preservation be discussed and initiated? 1 14.3 6 86 7
Who should be involved in the counseling and
decision making regarding fertility preservation?
1 7.7 12 92.3 13
What are the ethical and logistical aspects? 0 0.0 9 100 9
Total 6 12.8 41 87.2 47
Abbreviation: CPG, clinical practice guideline.
a Concordant guideline areas were those that presented the same recommendation in all CPGs.
bDiscordant guideline areas were those that did not present the same recommendation in all CPGs, those guideline areas that did not have a recommenda-
tion, or if only 1 CPG covered a guideline area.
TABLE 3. Concordant and Discordant Guideline Areas in High-Quality Male Fertility Preservation CPGs
Concordanta % per Row Discordantb % per Row Total
Who should be advised to receive fertility preservation? 2 20.0 8 80.0 10
What fertility preservation method should be used? 1 12.5 7 87.5 8
When should fertility preservation be discussed and initiated? 1 12.5 7 87.5 8
Who should be involved in the counseling and decision making
about fertility preservation?
0 0.0 13 100.0 13
What are the ethical and logistical aspects? 1 20.0 4 80.0 5
Total 5 11.4 39 88.6 44
Abbreviation: CPG, clinical practice guideline.
a Concordant guideline areas were those that presented the same recommendation in all CPGs.
bDiscordant guideline areas were those that did not present the same recommendation in all CPGs, those guideline areas that did not have a recommenda-
tion, or if only 1 CPG covered a guideline area.
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omitting recommendations for specific guideline areas.
The lack of available evidence or the low level of existing
evidence in the field of fertility preservation for CAYAs with
cancer is very likely to contribute to the variation observed.
Future research studies in this evolving field of clinical can-
cer practice will help to improve the available evidence,
thereby contributing tomore comprehensive fertility preser-
vation CPGs. Although nearly all CPG recommendations
included the need to involve the multidisciplinary team in
counseling and decision making regarding fertility preserva-
tion, not all of them explicitly mentioned the need for the
involvement of patients, parents, and advocacy groups in
the discussions. A systematic review revealed data indicating
that adolescents are very keen to be part of decisions related
to their cancer treatment and many have worries about their
fertility, but additional research is needed to explore the
content of the counseling and the role of adolescents and
parents with regard to fertility.46
We observed no concordance related to the key issue
“What are the ethical and logistical aspects?” in recom-
mendations for female patients with cancer and only 1
concordant guideline area for recommendations for male
patients with cancer. The unique ethical issues surround-
ing fertility preservation discussions with minors and dis-
cussions of experimental treatments involve a
considerable amount of uncertainty and can play a role in
these variations.47 Another likely explanation is national
differences in the legal aspects of informed consent; stor-
age of oocytes, embryos, ovarian tissue, and sperm; and
the costs involved with the procedures. As an example, we
observed that the NVOG recommended that oocytes,
embryos, and ovarian tissue be stored for a period of up to
40 years whereas NICE recommended a maximum of 55
years, with an initial period of 10 years. We found a high
degree of concordance for the guideline areas covering fer-
tility preservation methods and populations at risk of fer-
tility impairment. Although all CPGs that recommended
ovarian tissue cryopreservation included a statement con-
cerning its experimental nature, the NICE guideline did
not explicitly recommend this procedure because of the
lack of evidence to support future successful fertility based
on their literature searches. In addition, all the CPGs that
included ovarian tissue cryopreservation in their recom-
mendations mentioned the risk of reintroducing malig-
nant cells with grafting. The CPG from the COSA
explicitly included the recommendation to test the ovar-
ian tissue for the presence of cancer cells or markers.
Only approximately one-third of the identified CPGs
concerned with fertility preservation for CAYAs with can-
cer met our criteria for high quality. Our critical assessment
of the CPG methodology revealed very low AGREE II do-
main scores on guideline implementation. Although tools
to facilitate application such as summary documents and
links to algorithms were often found in the high-quality
CPGs, pilot testing of the guideline recommendations or
criteria to assess the impact of the implementation and
usability of the application tools were lacking. Similar find-
ings have been shown when assessing the quality of oncol-
ogy48 and pediatric49 CPGs in general. This highlights the
importance of establishing strategies during the guideline
development process that can improve adherence to the
recommendations. Some authors have warned of the risks
of large investments to develop and disseminate CPGs
without successful implementation, and emphasized the
need for an approach that integrates not only physicians as
stakeholders but also patients.50
Although the CPG by Fernbach et al22 was consid-
ered high quality, it scored very low on the domains of
stakeholder involvement and applicability. This is likely
to be related to the fact that the intent of their CPG was to
produce a summary of recommendations supported by
evidence using a rigorous development method, but not
to develop an official CPG.
We found that the Australian guideline27 scored the
lowest for the domain of editorial independence. Com-
peting risks of authors or funding bodies may have had an
influence on the recommendations for fertility preserva-
tion we identified. However, because AGREE II only
assesses the reported quality of the guideline development,
there is a possibility that the criteria were met but not spe-
cifically reported.
A strength of the current study was the use of an
objective instrument in the form of AGREE II to assess the
quality of the CPGs. In addition, we reduced the chance of
misinterpretation or missing information with regard to
the AGREE II items among the appraisers by discussing in
detail the items that differed by3 points. One study that
also used AGREE II to evaluate guidelines regarding fertil-
ity preservation for reproductive-age patients with breast
cancer revealed a wide variability in the recommenda-
tions.51 The findings of the current study underscore that
the lack of uniformity in recommendations for fertility
preservation is not limited to one patient group or tumor
type, but exists in CAYAs with all tumor types.
A limitation of the current study was that we only
selected CPGs written in English or Dutch, and this implies
the risk of potentially missing well-developed non-English
or non-Dutch CPGs (selection bias). However, we expect
this risk to be small because we asked international experts
in the fields of pediatric oncology and gynecology and
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within the PanCareLIFE Consortium for additional
evidence-based CPGs. Another limitation could be that
AGREE II does not differentiate between the relative im-
portance of the domains. However, in our opinion, the
AGREE II domains are not equally important. AGREE II
does not provide specific advice regarding how to present an
overall assessment. Thus, we chose not to provide an overall
judgment, which in our opinion is too subjective to report.
The current study was the starting point for the de-
velopment of a harmonized guideline for fertility preser-
vation within the European PanCareLIFE project.
PanCareLIFE is taking steps to generate transparent and
cohesive CPGs for fertility preservation for children facing
gonadotoxic therapies with the objective of guiding clini-
cal practice internationally by including experts from
within and outside Europe. In addition, political, reli-
gious, and legal issues surrounding fertility preservation
are taken into account in this guideline development pro-
ject because we involved a multidisciplinary group of
experts (including ethicists) in the working groups.
An essential part of the work of the PanCareLIFE
Consortium is to establish networks to ensure interna-
tional expertise and efforts; to avoid duplication of work;
to use evidence-based, robust methods; and to harmonize
recommendations.18 Previous international efforts to de-
velop recommendations for the surveillance (not care) of
survivors of childhood cancer indicated that such a world-
wide endeavor is feasible.17 The International Guideline
Harmonization Group has already published several
worldwide, harmonized, evidence-driven surveillance rec-
ommendations based on this methodology to decrease
discordances between national groups.52,53
The results of the current study indicate that recom-
mendations for fertility preservation vary across fertility
preservation CPGs that currently are in place for CAYAs
with cancer. It is conceivable that the lack of uniformity in
recommendations reflects the inadequate evidence for spe-
cific recommendations, thereby hindering the ability of pro-
viders to deliver high-quality care. CPGs that include
transparent and harmonized advice for fertility preservation
counseling can help health care providers to deliver optimal
and uniform care that may translate into a quality-of-life
benefit for CAYA patients with cancer and cancer survivors.
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